BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35700629)

  • 1. Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography.
    Grover H; King W; Bhattarai N; Moloney E; Sharp L; Fuller L
    Lung Cancer; 2022 Aug; 170():20-33. PubMed ID: 35700629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations.
    Behr CM; Oude Wolcherink MJ; IJzerman MJ; Vliegenthart R; Koffijberg H
    Pharmacoeconomics; 2023 Apr; 41(4):395-411. PubMed ID: 36670332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.
    Zhao Z; Wang Y; Wu W; Yang Y; Du L; Dong H
    JAMA Netw Open; 2022 May; 5(5):e2213634. PubMed ID: 35608858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.
    Snowsill T; Yang H; Griffin E; Long L; Varley-Campbell J; Coelho H; Robinson S; Hyde C
    Health Technol Assess; 2018 Nov; 22(69):1-276. PubMed ID: 30518460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
    Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
    Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of screening for lung cancer with low-dose computed tomography: a systematic literature review.
    Puggina A; Broumas A; Ricciardi W; Boccia S
    Eur J Public Health; 2016 Feb; 26(1):168-75. PubMed ID: 26370440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions.
    Villanti AC; Jiang Y; Abrams DB; Pyenson BS
    PLoS One; 2013; 8(8):e71379. PubMed ID: 23940744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-effectiveness of lung cancer screening worldwide: a systematic review].
    Liu CC; Shi JF; Liu GX; Tang W; Zhang X; Li F; Wang L; Ma Y; Su K; Zhao SJ; Gao YB; Li N; Chen WQ; Wu N; Dai M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):218-226. PubMed ID: 30744276
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review.
    Raymakers AJN; Mayo J; Lam S; FitzGerald JM; Whitehurst DGT; Lynd LD
    Appl Health Econ Health Policy; 2016 Aug; 14(4):409-418. PubMed ID: 26873091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shall We Screen Lung Cancer With Low-Dose Computed Tomography? Cost-Effectiveness in Hungary.
    Nagy B; Szilberhorn L; Győrbíró DM; Moizs M; Bajzik G; Kerpel-Fronius A; Vokó Z
    Value Health Reg Issues; 2023 Mar; 34():55-64. PubMed ID: 36502786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
    Kowada A
    BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.
    Zhao Z; Gu S; Yang Y; Wu W; Du L; Wang G; Dong H
    BMC Cancer; 2024 Jan; 24(1):73. PubMed ID: 38218803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness.
    Zeng X; Zhou Z; Luo X; Liu Q
    Front Public Health; 2022; 10():977550. PubMed ID: 36249202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
    Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
    J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
    Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis.
    Diaz M; Garcia M; Vidal C; Santiago A; Gnutti G; Gómez D; Trapero-Bertran M; Fu M;
    Lung Cancer; 2021 Sep; 159():153-161. PubMed ID: 34352591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Jaine R; Kvizhinadze G; Nair N; Blakely T
    Lung Cancer; 2018 Oct; 124():233-240. PubMed ID: 30268467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.
    Evans WK; Gauvreau CL; Flanagan WM; Memon S; Yong JHE; Goffin JR; Fitzgerald NR; Wolfson M; Miller AB
    CMAJ Open; 2020; 8(3):E585-E592. PubMed ID: 32963023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HUNCHEST-II contributes to a shift to earlier-stage lung cancer detection: final results of a nationwide screening program.
    Kerpel-Fronius A; Megyesfalvi Z; Markóczy Z; Solymosi D; Csányi P; Tisza J; Kecskés A; Baranyi B; Csánky E; Dóka A; Gálffy G; Göcző K; Győry C; Horváth Z; Juhász T; Kállai Á; Kincses ZT; Király Z; Király-Incze E; Kostyál L; Kovács A; Kovács A; Kuczkó É; Makra Z; Maurovich Horvát P; Merth G; Moldoványi I; Müller V; Pápai-Székely Z; Papp D; Polgár C; Rózsa P; Sárosi V; Szalai Z; Székely A; Szuhács M; Tárnoki D; Tavaszi G; Turóczi-Kirizs R; Tóth L; Urbán L; Vaskó A; Vigh É; Dome B; Bogos K
    Eur Radiol; 2024 May; 34(5):3462-3470. PubMed ID: 37921926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Lung Cancer Screening in Canada.
    Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
    JAMA Oncol; 2015 Sep; 1(6):807-13. PubMed ID: 26226181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.